aztreonam lysine (Cayston)

following a re-submission considered under the orphan process

aztreonam lysine (Cayston®) is accepted for restricted use within NHS Scotland.

Indication under review: Suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older.

SMC restriction: When inhaled colistimethate sodium and inhaled tobramycin are not tolerated or not providing satisfactory therapeutic benefit (measured as ≥2% decline in forced expiratory volume in 1 second [FEV1]).

Aztreonam lysine has demonstrated superiority in improving lung function and respiratory symptoms in one active-controlled study and two 28-day placebo-controlled studies in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection.

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of aztreonam lysine. It is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.